scholarly journals An elevated serum level of endothelial monocyte activating polypeptide-II in patients with arterial hypertension with and without type 2 diabetes and obesity

2016 ◽  
Vol 13 (3) ◽  
pp. 49-53 ◽  
Author(s):  
Liliya Mogylnytska ◽  
Boris Mankovsky
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Serum Level ◽  
Arterial Hypertension ◽  
Serum Insulin ◽  
Elevated Serum ◽  
Hypertensive Patients ◽  
Emap Ii

Objectives: To assess serum levels of endothelial monocyte activating polypeptide-II (EMAP-II) in patients with arterial hypertension with and without type 2 diabetes mellitus and obesity.Materials and methods: We examined 41 hypertensive patients with type 2 diabetes, 18 obese hypertensive patients without diabetes, 9 non-obese hypertensive patients without diabetes, and 18 healthy control subjects.Results: We found an increased serum level of EMAP-II in hypertensive patients with type 2 diabetes compared to controls (4.86±2.3 and 1.08±0.53 ng/ml respectively, р0.01), in hypertensive patients with obesity (2.92±1.42 ng/ml) compared to controls, and in non-obese hypertensive patients (2.02±0.33 ng/ml) compared to controls. Also, the levels of EMAP-II significantly correlated with HbA1c, blood glucose, serum insulin levels, HOMA, lipids, and body mass index (р0.01).Conclusions: The revealed changes could reflect an endothelial dysfunction mostly pronounced in patients with arterial hypertension, type 2 diabetes mellitus and obesity. Hyperglycemia, dyslipidemia, insulin resistance, obesity appear to be significant contributing factors leading to the elevation of EMAP-II.

scholarly journals Complex laboratory-instrumental and prognostic assessment in hypertensive patients with type 2 diabetes mellitus and atrial fibrillation

2012 ◽  
Vol 18 (1) ◽  
pp. 32-36
Author(s):  
T. S. Sveklina ◽  
A. V. Barsukov ◽  
M. S. Talantseva ◽  
S. B. Shustov
Keyword(s):  
Diabetes Mellitus ◽  
Atrial Fibrillation ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Survival Rate ◽  
Arterial Hypertension ◽  
High Density Lipoproteins ◽  
Hypertensive Patients ◽  
Prognostic Assessment

Objective. To perform a complex laboratory and instrumental and prognostic assessment of hypertensive subjects with type 2 diabetes mellitus (DM) and atrial fibrillation (AF). Design and methods. Based on the retrospective analysis out of 3150 case records we selected 443 clinical cases of arterial hypertension combined with type 2 diabetes mellitus (DM 2) and with or without atrial fibrillation (AF). They were divided into groups: 1st group included hypertensive patients with DM 2 and AF; 2nd — hypertensives with DM 2, and third — hypertensives with AF. We analyzed haemodynamic, electro-and echocardiography, routine biochemical (blood sugar, glycated hemoglobin, uric acid, potassium, microalbuminuria, cholesterol, low and high density lipoproteins, triglyceride, prothrombin and international normalized ratio, C-reactive protein) parameters, as well as adipokine levels (tumor necrosis factor alpha, adiponectine, leptine, resistine). Kaplan-Meyer’s analysis was performed to assess survival rate. Results. Patients from the 1st group showed subclinical target organ damage, dysregulation of metabolism and hormonal and regulatory activity. Compared to other groups these patients demonstrated a lower survival rate. Conclusion. The association of arterial hypertension, DM 2 and AF can be considered as a mutual burdening phenomenon, increasing the cardiovascular risk.

Correlation between TNF-α- serum level and TNF-α -308 gene polymorphism in Iraqi patients with type 2 diabetes mellitus

Gene Reports ◽  
2021 ◽  
Vol 23 ◽  
pp. 101136
Author(s):  
Sarah Rahman Rasool ◽  
Othman Taha Qasim ◽  
Salaam Khudhur Muslem ◽  
Muataz Mohammed Al-Taee
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Serum Level ◽  
Gene Polymorphism ◽  
Tnf Α

Left Ventricular Geometry and Function in Normotensive and Hypertensive Patients with Type 2 Diabetes Mellitus without Overt Cardiac Symptoms

2021 ◽  
Vol 4 (1) ◽  
Author(s):  
GA Amusa ◽  
SU Uguru ◽  
BI Awokola
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Left Ventricular ◽  
Left Ventricular Geometry ◽  
Hypertensive Patients ◽  
Lv Dysfunction ◽  
Cardiac Symptoms ◽  
And Function

Cardiovascular disease (CVD) is a common cause of morbidity/mortality in patients with type 2 diabetes mellitus (T2DM). Echocardiography can detect changes in cardiac geometry/function before overt CVD symptoms. This study aimed to evaluate left ventricular (LV) geometry and function in normotensive/hypertensive patients with T2DM without overt cardiac symptoms. A cross-sectional study in which fifty normotensives and fifty hypertensive adults with DM without overt cardiac symptoms were enrolled from the cardiology/diabetes clinics of Jos University Teaching Hospital (JUTH) in a simple random manner. Relevant history, physical examination and biochemical investigations were performed. 12-lead electrocardiography and echocardiograph assessment of LV geometry and function were also performed. Data was analyzed using Epi-info 7 statistical software; p value < 0.05 was considered significant. There were 27 females and 29 females in both groups. The prevalence of abnormal LV geometry was 36.0%, 95% CI 33.2-38.8% and 58.0%, 95% CI 55.2-60.8% in the normotensive and hypertensive groups respectively, P=0.028. Similarly, the prevalence of LV dysfunction was 38.0%, 95%CI 35.2-40.8% and 62.0%, 95%CI 59.2-64.8% respectively, P=0.017. The independent predictors of LV dysfunction were found to be duration of diabetes (OR 7.74, 95%CI 4.46-10.46), duration of hypertension ≥5years (OR 4.15, 95%CI 4.01-9.27), smoking (OR 4.34, 95%CI 1.32-6.23), body mass index ≥25 (OR 5.53, 95%CI 1.38-2.09) and glycosylated haemoglobin ≥7 (OR 7.11, 95%CI 2.15-0.81).  There is high prevalence of LV dysfunction/abnormal LV geometry in T2DM patients without overt cardiac symptoms; co-morbid hypertension worsens these abnormalities. Early and periodic echocardiography is recommended with appropriate intervention in these patients.

Sign in / Sign up

Export Citation Format

Share Document